Nature’s Remedies: Exploring the Potential of Propolis to Alleviate Non-Motor Manifestations of Parkinson’s Disease

Molecules, Journal Year: 2025, Volume and Issue: 30(8), P. 1672 - 1672

Published: April 8, 2025

Parkinson’s disease (PD) is a complex neurodegenerative disorder with debilitating non-motor symptoms, including gastrointestinal dysfunction, cardiovascular abnormalities, mood and anxiety disorders, cognitive decline, sleep disturbances, respiratory pain. Despite their significant impact on quality of life, these symptoms are often inadequately addressed. Propolis natural bee-derived product, rich in bioactive compounds anti-inflammatory, antioxidant, immunomodulatory, neuroprotective properties, which holds potential PD due to its multitarget multipathway actions, addressing various underlying mechanisms symptom diseases. Preclinical clinical studies suggest that propolis may influence key pathological PD’s symptoms. Evidence points benefits improving cognition, health, alleviating sleep-related issues. Although research remains scarce, findings from related conditions ability associated This review underscores the underexplored therapeutic PD, drawing existing evidence advocating for further fully assess role patient outcomes.

Language: Английский

---

Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression

Journal of Neural Transmission, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Abstract Treatment with levodopa, a precursor of dopamine (DA), to compensate for the loss endogenous DA in Parkinson’s disease (PD), has been success story over 50 years. However, late stages PD, progressive degeneration dopaminergic neurons and ongoing reduction concentrations make it increasingly difficult maintain normal-like function. Typically, higher doses levodopa are required, fluctuations striatal concentrations—reflecting timing pattern administrations—become more pronounced. These can include highs that induce involuntary movements (levodopa-induced dyskinesia, LID) or lows result insufficient suppression PD symptoms (“OFF” phases). The enhanced primarily arise from buffering capacity, resulting neurons, an increased reliance on levodopa-derived release as “false neurotransmitter” by serotonergic neurons. In many patients, LID OFF-phases be alleviated modifying therapy provide continuous delivery using additional medications, such monoamine oxidase-B (MAO-B) inhibitors, amantadine, receptor agonists. Understanding challenges faced also requires considering striatum is characterized not only but neuroplastic adaptations PD-induced degenerations other neural populations. This review provides broad overview use treating focus underlying science encountered disease.

Language: Английский

---

Towards the quantum-enabled technologies for development of drugs or delivery systems

Journal of Controlled Release, Journal Year: 2020, Volume and Issue: 324, P. 260 - 279

Published: May 4, 2020

Language: Английский

---

From the Gut to the Brain: Is Microbiota a New Paradigm in Parkinson’s Disease Treatment?

Cells, Journal Year: 2024, Volume and Issue: 13(9), P. 770 - 770

Published: April 30, 2024

Parkinson’s disease (PD) is recognized as the second most prevalent primary chronic neurodegenerative disorder of central nervous system. Clinically, PD characterized a movement disorder, exhibiting an incidence and mortality rate that increasing faster than any other neurological condition. In recent years, there has been growing interest concerning role gut microbiota in etiology pathophysiology PD. The establishment brain–gut axis now real, with evidence denoting bidirectional communication between brain through metabolic, immune, neuronal, endocrine mechanisms pathways. Among these, vagus nerve represents direct form gut. Given potential interactions bacteria drugs, it observed therapies for can have impact on composition microbiota. Therefore, scope present review, we will discuss current understanding whether this may be new paradigm treating devastating disease.

Language: Английский

---

Genetic heterogeneity of early onset Parkinson disease: The dilemma of clinico-genetic correlation

Parkinsonism & Related Disorders, Journal Year: 2024, Volume and Issue: unknown, P. 107146 - 107146

Published: Sept. 1, 2024

Language: Английский

---